FOCUS: HIV
Appeal for cost of generic long-acting HIV drug to be lowered
Health activists have urged pharmaceutical manufacturer Gilead Sciences to lower the price of its twice-yearly, long-acting injection for HIV prevention, saying the jab – which was recently approved by the US Food & Drug Administration (FDA) – will not live up to its potential if it remains unaffordable for the governments and people who need it most.
The FDA approval paves the way for regulators in other countries to follow suit, reports BusinessLIVE.
Lenacapavir, branded Yetzugo, has been hailed a potential...